Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.


NDAQ:IPA - Post by User

Post by theNormon Feb 04, 2021 4:43pm
238 Views
Post# 32477669

Weakness until deal closes Feb 8

Weakness until deal closes Feb 8IPA had to give up on the price to get HC Wainwright to offer without warrants.  I am embracing this offering because it gives me time to raise cash and add on the cheap.  Only HCW got 7% compensation warrants that have a 15% premium in IPA's favour.  They'll compensate IPA for commissions paid, if HCW uses them within 30 days.
  If Polytope results are good this is a quick triple minimum.  Gates backed vaccine was a 5 bagger awhile back on news, the very first day.    IPA  is ridiculously undervalued right now. 
  This is all good, unappreciative US investors sold in droves down to the new price giving everyone liquidity on the Nasdaq and the ability to load up on the cheap.

Cheers  


<< Previous
Bullboard Posts
Next >>